News | February 02, 2015

Abbott’s High Sensitive Troponin Test May Double Diagnosis of Women’s Myocardial Infarction

Test features gender-specific cutoffs, may reduce evaluation time by several hours

Abbott, troponin, women, myocardial infarction, blood testing, diagnosis

February 2, 2015 — The British Medical Journal published results online that show Abbott’s Architect Stat High Sensitive Troponin-I (hsTnl) test may help doctors to detect twice as many myocardial infarctions (MI) in women. Results showed that Abbott’s test was able to diagnose MI in 22 percent of cases for women compared to a standard of 11 percent, when using a sex-specific threshold.

The study was funded by a special project grant from the British Heart Foundation. It was conducted by researchers at the University of Edinburgh and collected data from 1,126 patients to evaluate the use of Abbott’s test in diagnosing MI.

Abbott’s test can precisely measure very low levels of cardiac troponin, a protein which at increased levels can indicate injury to the heart. This is especially important for women, who often have lower levels of troponin than men. As a result, some women may have their heart attacks undetected and undiagnosed. These factors, as well as others, contribute to inequalities in the diagnosis and treatment of women.

“Women are likely to have poorer outcomes following a heart attack compared to men of the same age,” said Anoop Shah, M.D., one of the study authors from the University of Edinburgh. “While men and women are just as likely to present to the emergency department with chest pain, men are currently twice as likely to be diagnosed with a heart attack. The high sensitive troponin test, with gender specific thresholds for men and women, may diagnose more heart attacks in women, and identify women at high risk who may benefit from targeted evidence based therapy.”

The National Institute for Health and Care Excellence (NICE) recommended Abbott’s hsTnl test, among others, in October 2014 to help doctors quickly rule out heart attacks in NHS emergency departments in England and Wales. By using Abbott’s hsTnI test, doctors may reduce the time for evaluating heart attacks by several hours compared to standard troponin tests. Among the tests included in this guidance, only Abbott’s hsTnI test offers gender specific cutoffs.

Abbott’s hsTnI test is commercially available in in Europe, as well as Canada, Australia, New Zealand, and Brazil. The test runs on Abbott’s fully automated Architect family of analyzers.

For more information:


Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init